Cheryl Zimberlin

ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next we will use the unique advantages of our cellular source to tackle solid tumors. Platform ImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood. Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with the ability to differentiate into cell types including NK cells, T cells and macrophages. Pipeline In the near term, our goal is to validate the economic and clinical benefits of our expansion technology by taking an expanded-HSC-derived NK cell to clinical trials for hematological malignancies. In the long term, our unique access to the modified and unmodified immune tree allows us to tackle the challenge of solid tumors with combinations of modified cells. Agile Discovery This agile and flexible allogeneic platform reduces costs of discovery and manufacturing, expanding commercially viable indications for cellular immunotherapy. Starting from cord blood has speed and cost advantages over iPSCs, including the ability to quickly match HLA types to target populations or select beneficial genotypes without the need to edit those features into a clonal iPS line. This enables rapid iterations of abundant and consistent sources of therapeutic cells.

Scipio Bioscience, a Paris-based biotechnology company, provides novel sample preparation solutions for single-cell studies in the form of easy-to-use benchtop kits and intuitive, cloud-based software. Scipio Bioscience exploits a proprietary technology for barcoding for preparation of samples for single-cell profiling. The initial target of Scipio Bioscience is to provide sample preparation for single-cell transcriptomics freed of the substantial investment and running costs of existing technologies, while attaining the flexibility and scalability required in state-of-the-art research. The blooming applications in single-cell transcriptomics have revealed the importance of characterizing the diversity of cell profiles in normal tissues and cancerous tumors. For optimal results, numbers of cells in the range of thousands must be analyzed simultaneously by RNA-sequencing procedures. The costs and constraints of available methods for sample preparation have hampered widespread adoption of this approach. Scipio Bioscience overcomes these obstacles by providing a test-tube solution readily accessible to laboratories in all fields of biological research. The first outcome of this technology was the commercial release of the Asteria™ Single-cell RNA-seq Kit and its companion data analysis software Cytonaut™ in May 2022. Able to analyze 10,000 input cells in a single-tube, the kit bypasses the use of microfluidics or plate in favor of a simple, accessible protocol that is easier on cells and enables a stable stopping point 2 hours in. The resulting sequencing data can be analyzed with Cytonaut™, a cloud-based software that covers the entire 3’ scRNA-seq data analysis chain and emphasizes on the ease-of-use for biologists and bioinformaticians alike. Scipio bioscience is housed in the Paris Santé Cochin incubator, located in the celebrated Parisian Cochin Hospital.

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. Its proprietary Esterase Motif Technology (ESM) platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner, activating the body's natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers. Founded by the CRT Pioneer Fund (CPF), the Company recently raised £9 million in a Series A financing round, led by CPF and two new specialist investors, Novo A/S and Aglaia Biomedical Ventures BV. Macrophage Pharma’s strategy is to complete the preclinical development of its lead development candidate, a p38 MAP kinase inhibitor, and advance two additional discovery candidates into pre-clinical development. The company's management team, led by Dr Søren Bregenholt, Chief Executive Officer, has a track record of success in the pharma industry ranging from early discovery to commercialisation. The Scientific Advisory Board is comprised of world-leading immunologists and cancer researchers who will help shape the future development of the company’s unique approach in immuno-oncology. For more information, please visit the company website: www.macrophagepharma.com

Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

Multitude Therapeutics (MTX) is a spinoff company created by Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing novel antibody-drug conjugates (ADC), CAR-Ts and immuno-oncology antibodies for solid and hematological tumors. MTX’s therapeutic programs are based on novel cancer and immune cell surface targets discovered by monoclonal antibody arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by the exceptional antibody discovery capabilities built at Abmart.

Indi Molecular is developing protein catalyzed capture (PCC) agents as a small synthetic molecule replacement for antibody-based therapeutics. PCCs are poised to play a central role in therapy given their ability to be deployed as both a precision in vivo PET diagnostic and as a targeted therapeutic. For radiotherapy this dual role is accomplished by choice of the complexed radionuclide sharing the same chelation chemistry. Chemotherapy can similarly be specifically delivered to diseased cells by the protein catalyzed capture technology. The company launched in 2013 with a $1.8 million seed round, followed by an $11.5 million Series A in 2017.

VAXIMM is a privately held, Swiss/German biotech company that is developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s product platform is based on a live attenuated, safe, orally available bacterial vaccine strain, which is modified to stimulate patients’ cytotoxic T-cells to target specific structures of the tumor. The Company has a pipeline of complementary development candidates targeting different tumor structures. Lead product candidate, oral VXM01, activates killer cells targeting tumor-specific vasculature and certain immune-suppressive cells, thereby increasing immune cell infiltration in solid tumors. VXM01 is currently in clinical development for several tumor types, including brain cancer. VAXIMM has completed a clinical trial evaluating VXM01 in combination with the human anti-PD-L1 antibody, avelumab, as part of a scientific collaboration with Merck KGaA, Darmstadt, Germany. VAXIMM also has a collaboration agreement with China Medical System Holdings (CMS), granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s existing programs. VAXIMM AG is headquartered in Basel, Switzerland. Its wholly owned subsidiary, VAXIMM GmbH, located in Mannheim, Germany, is responsible for the Company’s development activities.

As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant…nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival. ApoGen Biotechnologies is developing novel oncology therapeutics targeting the key drivers of mutation and cancer genomic evolution to overcome drug resistance. (www.apogenbiotech.com)

Calypso Biotech is a biopharmaceuticals company that discovers and develops novel therapies for auto-immune diseases.

Calypso Biotech is a biopharmaceuticals company that discovers and develops novel therapies for auto-immune diseases.

Rewind Therapeutics is developing first-in-class remyelinating therapies for myelin-related diseases and aims to bring them into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition and movement, among others. The causes of damage may be genetic, a result of infectious or autoimmune disease or from exposure to toxic agents or other forms of brain injury. There is no cure for demyelinating diseases. The Company was founded by KU Leuven’s Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. (Milano, Italy), a leading provider of integrated discovery services for the Life Sciences. Rewind Therapeutics works in close collaboration with both organisations and a world-class academic network to advance its discovery and development activities. Rewind Therapeutics is backed by life science investors Boehringer Ingelheim Venture Fund, M Ventures and the Flemish investment company PMV, together with CD3 and KU Leuven Gemma Frisius Fonds.

Rewind Therapeutics is developing first-in-class remyelinating therapies for myelin-related diseases and aims to bring them into fast-track clinical development. Myelin-related diseases, such as multiple sclerosis, are those where the myelin sheath surrounding nerves is damaged leading to deficient nerve transmission that may affect multiple functions, including sensation, cognition and movement, among others. The causes of damage may be genetic, a result of infectious or autoimmune disease or from exposure to toxic agents or other forms of brain injury. There is no cure for demyelinating diseases. The Company was founded by KU Leuven’s Centre for Drug Design and Discovery (CD3) and Axxam S.p.A. (Milano, Italy), a leading provider of integrated discovery services for the Life Sciences. Rewind Therapeutics works in close collaboration with both organisations and a world-class academic network to advance its discovery and development activities. Rewind Therapeutics is backed by life science investors Boehringer Ingelheim Venture Fund, M Ventures and the Flemish investment company PMV, together with CD3 and KU Leuven Gemma Frisius Fonds.

Ligase Biopartners is a science-first investor, partnering with researchers to translate early-stage science into meaningful ventures — driven by courage, humanity, and patient impact.

ImmuneBridge is developing allogeneic immunotherapies for cancer. Our core technology drives the expansion of cord blood derived immune stem cells and establishes a novel, flexible, consistent and abundant cellular source for immunotherapies. We are currently pursuing natural killer cell products for hematological malignancies. Next we will use the unique advantages of our cellular source to tackle solid tumors. Platform ImmuneBridge is creating a platform of scalable allogeneic immune cell therapies from cord blood. Our proprietary technology, including a novel small molecule, expands cord blood HSPCs over 100,000-fold while maintaining full immune multipotency, with the ability to differentiate into cell types including NK cells, T cells and macrophages. Pipeline In the near term, our goal is to validate the economic and clinical benefits of our expansion technology by taking an expanded-HSC-derived NK cell to clinical trials for hematological malignancies. In the long term, our unique access to the modified and unmodified immune tree allows us to tackle the challenge of solid tumors with combinations of modified cells. Agile Discovery This agile and flexible allogeneic platform reduces costs of discovery and manufacturing, expanding commercially viable indications for cellular immunotherapy. Starting from cord blood has speed and cost advantages over iPSCs, including the ability to quickly match HLA types to target populations or select beneficial genotypes without the need to edit those features into a clonal iPS line. This enables rapid iterations of abundant and consistent sources of therapeutic cells.

Scipio Bioscience, a Paris-based biotechnology company, provides novel sample preparation solutions for single-cell studies in the form of easy-to-use benchtop kits and intuitive, cloud-based software. Scipio Bioscience exploits a proprietary technology for barcoding for preparation of samples for single-cell profiling. The initial target of Scipio Bioscience is to provide sample preparation for single-cell transcriptomics freed of the substantial investment and running costs of existing technologies, while attaining the flexibility and scalability required in state-of-the-art research. The blooming applications in single-cell transcriptomics have revealed the importance of characterizing the diversity of cell profiles in normal tissues and cancerous tumors. For optimal results, numbers of cells in the range of thousands must be analyzed simultaneously by RNA-sequencing procedures. The costs and constraints of available methods for sample preparation have hampered widespread adoption of this approach. Scipio Bioscience overcomes these obstacles by providing a test-tube solution readily accessible to laboratories in all fields of biological research. The first outcome of this technology was the commercial release of the Asteria™ Single-cell RNA-seq Kit and its companion data analysis software Cytonaut™ in May 2022. Able to analyze 10,000 input cells in a single-tube, the kit bypasses the use of microfluidics or plate in favor of a simple, accessible protocol that is easier on cells and enables a stable stopping point 2 hours in. The resulting sequencing data can be analyzed with Cytonaut™, a cloud-based software that covers the entire 3’ scRNA-seq data analysis chain and emphasizes on the ease-of-use for biologists and bioinformaticians alike. Scipio bioscience is housed in the Paris Santé Cochin incubator, located in the celebrated Parisian Cochin Hospital.

Macrophage Pharma is an immuno-oncology company focused on the discovery and development of novel therapies designed to enhance anti-tumour immune responses. Its proprietary Esterase Motif Technology (ESM) platform is designed to deliver small molecule drugs to tumour associated macrophages in a highly selective manner, activating the body's natural immune system to fight cancer. The platform has the ability to provide next-generation immunotherapies for a number of different cancers. Founded by the CRT Pioneer Fund (CPF), the Company recently raised £9 million in a Series A financing round, led by CPF and two new specialist investors, Novo A/S and Aglaia Biomedical Ventures BV. Macrophage Pharma’s strategy is to complete the preclinical development of its lead development candidate, a p38 MAP kinase inhibitor, and advance two additional discovery candidates into pre-clinical development. The company's management team, led by Dr Søren Bregenholt, Chief Executive Officer, has a track record of success in the pharma industry ranging from early discovery to commercialisation. The Scientific Advisory Board is comprised of world-leading immunologists and cancer researchers who will help shape the future development of the company’s unique approach in immuno-oncology. For more information, please visit the company website: www.macrophagepharma.com

Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.